Viatris (VTRS) is expected to deliver a year ... it's worth having a handicapping insight into the odds of a positive EPS surprise. This generic drugmaker is expected to post quarterly earnings ...

Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.

We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable. Sadly for Viatris, its EPS declined by 8.7% annually over the last five years ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Siddiq, Biotricity Founder & CEO, said, “In the third quarter of fiscal 2025, we continued our mission to innovate a ...

Reports Q4 revenue EUR65.68M from EUR65.30M last year. CEO Brigitte de Vet-Veithen commented, “In the final quarter of 2024 our Materialise ...

Revenue for Q4 2024 was $1.34 billion, surpassing the estimate by $25 million. Adjusted EPS was $0.05, missing expectations by $0.12. Net income improved to $33 million from a loss of $36 million ...

Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQ:VTRS). The end of the earnings season is always a good time to take a step back and see who ...

Shares of Viatris Inc. VTRS advanced 1.72% to $11.25 Friday, on what proved to be an all-around rough trading session for the ...

Shares of Viatris Inc. VTRS advanced 1.19% to $11.06 Thursday, on what proved to be an all-around dismal trading session for ...